[
  {
    "ts": "2026-02-13T11:15:18+00:00",
    "headline": "Is It Too Late To Consider Exact Sciences (EXAS) After The US$105 Abbott Offer",
    "summary": "If you are wondering whether Exact Sciences at around US$103 a share still offers value, you are not alone. This article is all about putting that price tag into context. The stock has returned 0.6% over the last 7 days, 1.0% over 30 days, 1.5% year to date and 104.1% over the past year, while the 3 year return sits at 61.9% and the 5 year return at a 27.1% decline. Recently, headlines have focused on Exact Sciences as a key player in cancer screening and diagnostics, with media coverage...",
    "url": "https://finance.yahoo.com/news/too-consider-exact-sciences-exas-111518854.html",
    "source": "Simply Wall St.",
    "provider": "yfinance",
    "raw": {
      "id": "9391c269-1a16-354a-ba10-60fcc5542e3b",
      "content": {
        "id": "9391c269-1a16-354a-ba10-60fcc5542e3b",
        "contentType": "STORY",
        "title": "Is It Too Late To Consider Exact Sciences (EXAS) After The US$105 Abbott Offer",
        "description": "",
        "summary": "If you are wondering whether Exact Sciences at around US$103 a share still offers value, you are not alone. This article is all about putting that price tag into context. The stock has returned 0.6% over the last 7 days, 1.0% over 30 days, 1.5% year to date and 104.1% over the past year, while the 3 year return sits at 61.9% and the 5 year return at a 27.1% decline. Recently, headlines have focused on Exact Sciences as a key player in cancer screening and diagnostics, with media coverage...",
        "pubDate": "2026-02-13T11:15:18Z",
        "displayTime": "2026-02-13T11:15:18Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/simply_wall_st__316/4d522452d0da08d8412701a84270533b",
          "originalWidth": 1194,
          "originalHeight": 432,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/FqD7IP1YjoMtOLiC1foWBQ--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/4d522452d0da08d8412701a84270533b.cf.webp",
              "width": 1194,
              "height": 432,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/DnvRJ7zmyZqa8oFdfcLgCg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/simply_wall_st__316/4d522452d0da08d8412701a84270533b.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Simply Wall St.",
          "url": "https://simplywall.st/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/too-consider-exact-sciences-exas-111518854.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/too-consider-exact-sciences-exas-111518854.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "EXAS"
            },
            {
              "symbol": "ABT"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]